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Inspite of extensive research in tuberculosis (TB),
it is still one of the major infectious diseases and
cause of high mortality world wide [Brewer et al.
2005]. To enhance efficacy with lower dosing,
newer drug delivery systems has been developed
which provide targeted drug delivery and
controlled release at the primary site of infection,
i.e., the lung macrophage. Our lab has previously
reported poly(D, L-lactic acid) (PLA)
microparticles containing rifabutin (RFB) and
isoniazid (INH) for pulmonary delivery and
explored various facets of treatment with
microparticle DPI Muttil et al. 2007]. The aim of
present study was to evaluate pharmacokinetics,
biodistribution and toxicity parameters of RFB and
INH incorporated in DPI microparticles after ninety
days of repeated dosing in rhesus macaques in
order to establish steady-state pharmacokinetics
and preclinical safety of the formulation prior to
humans clinical trials.
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OBJECTIVE
CONCLUSION
The data obtained from rhesus monkeys with
good therapeutic concentration in target organ
and negligible toxicity (data not shown)
strongly recommends for the further human
clinical trails
Plots representing the mean drug serum
concentration–time data after intravenous
administration of rifabutin and isoniazid to
monkeys are shown in figure-A. In contrast to
inhalation [Fig-B(100mg MP) & C (10mg MP)], i.v.
administration resulted in hasty clearance of
drugs from the blood, significantly shorter half-
lives and mean residence times. Dose-
dependant enhancement of all parameters was
observed, as expected from the order of
magnitude differences in doses. It could be seen
from figure that concentration of both the drugs
descends in order of lungs, liver and kidney. As
evident from figure, level of rifabutin and
isoniazid in lungs were much higher than tissue
than other tissues (Liver & Kidney). Serum
Cmax was 5.4 to 7 times greater with
intravenous compared to pulmonary delivery,
while serum t1/2 was 3.5 to 5.7 longer after
inhalation, demonstrating targeted as well as
controlled delivery. The biological half lives of
both agents were enhanced up to almost six
times by incorporation in inhalable MP. The
higher i.v. doses were retained longer, but much
less as compared to equivalent doses from
inhaled MP. Compared to mice, Tmax was
prolonged by ~2 h while t1/2 was shorter: ~10 h
for INH and ~14 h for RFB after DPI. The results
of this report suggests microparticles lead to
the deposition of drugs into the lungs of
monkeys by means of inhalation and maintain
high therapeutic concentration.
DISCUSSION
To evaluate pharmacokinetic and biodistribution 
of anti-tuberculosis  drugs in rhesus monkeys
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Prepared microparticles formulation has
physicochemical properties that render it
suitable for administration as a dry powder
inhalation (DPI). Microparticles containing
0.25(1mg MP), 2.5(10mg MP) or 25 mg(100mg
MP) each of isoniazid (INH) and rifabutin
(RFB) were administered daily for 90 days to
rhesus macaques (n=4/group). Another group
received single intravenous doses.
Serum was separated from blood samples of
each time point. After 90-day study, various
tissues of interest (lung, liver and kidney) were
harvested from twenty monkeys, minced into
pieces, homogenized and analyzed for drug
content. Validated HPLC method were used for
assay in serum, alveolar macrophages and
homogenates of lungs, liver and kidneys.
Pharmacokinetics were investigated using
WinNonlin. Biodistribution in cell lysate and
tissues was established at terminal sacrifice.
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